摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[5-((1S)-2-azido-1-hydroxyethyl)-2-hydroxyphenyl]methanesulfonamide | 300345-77-1

中文名称
——
中文别名
——
英文名称
N-[5-((1S)-2-azido-1-hydroxyethyl)-2-hydroxyphenyl]methanesulfonamide
英文别名
(R)-2-azido-1-(4-benzyloxy-3-methylsulfonylamino)phenylethanol;N-[5-((R)-2-azido-1-hydroxyethyl)-2-benzyloxyphenyl]methanesulfonamide;N-[5-[(1R)-2-azido-1-hydroxyethyl]-2-phenylmethoxyphenyl]methanesulfonamide
N-[5-((1S)-2-azido-1-hydroxyethyl)-2-hydroxyphenyl]methanesulfonamide化学式
CAS
300345-77-1
化学式
C16H18N4O4S
mdl
——
分子量
362.409
InChiKey
LMSLAXHVWQQDOH-HNNXBMFYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    25
  • 可旋转键数:
    8
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    98.4
  • 氢给体数:
    2
  • 氢受体数:
    7

反应信息

  • 作为反应物:
    描述:
    N-[5-((1S)-2-azido-1-hydroxyethyl)-2-hydroxyphenyl]methanesulfonamide 在 palladium on activated charcoal ammonium formate 作用下, 以 甲醇 为溶剂, 以76%的产率得到N-[5-((1R)-2-amino-1-hydroxy-ethyl)-2-hydroxy-phenyl]-methanesulfonamide
    参考文献:
    名称:
    Novel (4-Piperidin-1-yl)-phenyl Sulfonamides as Potent and Selective Human β3 Agonists
    摘要:
    A series of novel (4-piperidin-1-yl)-phenyl sulfonamides was prepared and evaluated for their biological activity on the human beta (3)-adrenergic receptor (AR). Replacement of the 3,4-dihydroxyl group of the catechol moiety with 4-hydroxyl-3-methyl sulfonamide on the left-hand side of the compounds resulted in a number of potent full agonists at the beta (3) receptor. Modification of the right-hand side of the compounds by incorporation of a free carboxylic acid resulted in a few potent human beta (3) agonists with low affinities for beta (1)- and beta (2)-ARs. N-Alkyl substitution on the 4-piperidin-1-yl-phenylamine further increased the beta (3) potency while maintaining the selectivity. For example, sulfonamide 48 is a potent full beta (3) agonist (EC50 = 0.004 muM, IA = 1.0) with > 500-fold selectivity over beta (1)- and beta (2)-ARs. (C) 2001 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(01)00114-6
  • 作为产物:
    描述:
    (R)-N-[5-(2-溴-1-羟乙基)-2-(苯基甲氧基)苯基]甲磺酰胺 在 sodium azide 、 sodium iodide 作用下, 以 二甲基亚砜 为溶剂, 反应 120.0h, 以94%的产率得到N-[5-((1S)-2-azido-1-hydroxyethyl)-2-hydroxyphenyl]methanesulfonamide
    参考文献:
    名称:
    Novel (4-Piperidin-1-yl)-phenyl Sulfonamides as Potent and Selective Human β3 Agonists
    摘要:
    A series of novel (4-piperidin-1-yl)-phenyl sulfonamides was prepared and evaluated for their biological activity on the human beta (3)-adrenergic receptor (AR). Replacement of the 3,4-dihydroxyl group of the catechol moiety with 4-hydroxyl-3-methyl sulfonamide on the left-hand side of the compounds resulted in a number of potent full agonists at the beta (3) receptor. Modification of the right-hand side of the compounds by incorporation of a free carboxylic acid resulted in a few potent human beta (3) agonists with low affinities for beta (1)- and beta (2)-ARs. N-Alkyl substitution on the 4-piperidin-1-yl-phenylamine further increased the beta (3) potency while maintaining the selectivity. For example, sulfonamide 48 is a potent full beta (3) agonist (EC50 = 0.004 muM, IA = 1.0) with > 500-fold selectivity over beta (1)- and beta (2)-ARs. (C) 2001 Elsevier Science Ltd. All rights reserved.
    DOI:
    10.1016/s0968-0896(01)00114-6
点击查看最新优质反应信息

文献信息

  • METHOD FOR THE PREPARATION OF TRICYCLIC AMINO ALCOHOL DERIVATIVES THROUGH AZIDES
    申请人:Asahi Kasei Kabushiki Kaisha
    公开号:EP1174426A1
    公开(公告)日:2002-01-23
    The present invention is directed to processes for the preparation of a tricyclic amino-alcohol derivative useful for treating and preventing diabetes, obesity, hyperlipidemia and the like, which compound is represented by the formula (1): wherein R1 represents a lower alkyl group or a benzyl group; *1 represents an asymmetric carbon atom; R2 represents a hydrogen atom, a halogen atom or a hydroxyl group; and A represents one of the following groups: wherein X represents NH, O or S; R5 represents a hydrogen atom, a hydroxyl group, an amino group or an acetylamino group; and *2 represents an asymmetric carbon atom when R5 is not a hydrogen atom. The processes of the present invention proceed via azide derivatives and are convenient, practical preparing processes with low cost which comprise a small number of steps with good industrial work efficiency.
    本发明涉及一种用于治疗和预防糖尿病、肥胖、高脂血症等疾病的三环氨基醇衍生物的制备方法,该化合物由以下式子表示(1): 其中R1代表较低的烷基或苄基;*1代表一个不对称碳原子;R2代表氢原子、卤素原子或羟基;A代表以下其中一种基团: 其中X代表NH、O或S;R5代表氢原子、羟基、氨基或乙酰氨基;*2代表一个不对称碳原子,当R5不是氢原子时。本发明的方法通过叠氮衍生物进行,是方便、实用、成本低廉的制备方法,包括少量步骤且具有良好的工业工作效率。
  • AMINO ALCOHOL DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, AND USE OF THESE
    申请人:Kissei Pharmaceutical Co., Ltd.
    公开号:EP1679304A1
    公开(公告)日:2006-07-12
    The present invention provides compounds represented by general formula (I): a prodrug thereof, or pharmaceutical acceptable salts thereof, wherein R1 is hydrogen or lower alkyl; each of R2 and R3 is independently hydrogen or lower alkyl; each of R4, R5 and R6 is independently hydrogen, halogen, lower alkyl or lower alkoxy; R7 is hydrogen or lower alkyl; R8 is hydrogen, halogen, lower alkyl, lower alkoxy, etc; R9 is -COR10, -A1-COR10, -O-A2-COR10, etc; Ar is optionally substituted phenyl or heteroaryl; and A is a bond, -OCH2-, etc, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.
    本发明提供了由通式(I)表示的化合物: 其前药,或其药用可接受的盐,其中R1是氢或较低的烷基;R2和R3中的每一个独立地是氢或较低的烷基;R4、R5和R6中的每一个独立地是氢、卤素、较低的烷基或较低的烷氧基;R7是氢或较低的烷基;R8是氢、卤素、较低的烷基、较低的烷氧基等;R9是-COR10、-A1-COR10、-O-A2-COR10等;Ar是可选择地取代的苯基或杂环芳基;A是键,-OCH2-等,具有强效和选择性的β3-肾上腺素受体刺激活性。本发明还提供了含有所述化合物的药物组合物,以及其用途。
  • N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
    申请人:American Home Products Corporation
    公开号:US20020028797A1
    公开(公告)日:2002-03-07
    This invention provides compounds of Formula I having the structure 1 wherein R 1 , R 2 , R 3 , R 4 , W, X, and Y are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
    这项发明提供了具有结构1的化合物,其中R1、R2、R3、R4、W、X和Y如前文所定义,或其药用盐,这些化合物可用于治疗与胰岛素抵抗或高血糖相关的代谢紊乱。
  • Cyclamine sulfonamides as beta-3 adrenergic receptor agonists
    申请人:American Home Products Corporation
    公开号:US20020022605A1
    公开(公告)日:2002-02-21
    This invention provides compounds of Formula I having the structure 1 wherein R 1 , R 2 , R 3 , W, X, and Z are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
    本发明提供了具有结构1的化合物,其中R1、R2、R3、W、X和Z如前所定义,或其药学上可接受的盐,这些化合物可用于治疗与胰岛素抵抗或高血糖相关的代谢性疾病。
  • 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
    申请人:Wyeth
    公开号:US20020169325A1
    公开(公告)日:2002-11-14
    This invention provides compounds of Formula I having the structure 1 wherein: A, X, Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.
    本发明提供了具有结构1的化合物,其公式为: 其中,A、X、Y、Z、R1、R2、R3、R4、R5和R6如前所定义,或其药学上可接受的盐,用于治疗或抑制与胰岛素抵抗或高血糖相关的代谢紊乱(通常与肥胖或葡萄糖不耐症相关)、动脉粥样硬化、胃肠道疾病、神经遗传性炎症和频繁排尿;特别适用于治疗或抑制2型糖尿病。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐